vs
富兰克林电气（FELE）与Royalty Pharma plc（RPRX）财务数据对比。点击上方公司名可切换其他公司
Royalty Pharma plc的季度营收约是富兰克林电气的1.2倍（$622.0M vs $500.4M），Royalty Pharma plc净利率更高（34.4% vs 6.9%，领先27.5%），富兰克林电气同比增速更快（9.9% vs 4.8%），过去两年Royalty Pharma plc的营收复合增速更高（4.6% vs -4.0%）
富兰克林电气是全球知名的水务与能源管理产品及系统制造分销商，主营泵类、电机、驱动器及控制设备，产品广泛应用于住宅、商用、农业、工业、市政等多元场景。公司总部位于美国印第安纳州韦恩堡，在美国、德国、捷克、意大利、土耳其、墨西哥、巴西、澳大利亚、南非等多个国家设有生产基地，为全球客户提供可靠的流体运输与能源管理解决方案。
本公司是总部位于美国马萨诸塞州剑桥市的临床阶段生物制药企业，专注于研发可调节转化生长因子β（TGF-β）超家族蛋白的药物，该类蛋白在红细胞、肌肉、骨骼、血管等细胞与组织的生长修复过程中发挥核心作用。
FELE vs RPRX — 直观对比
营收规模更大
RPRX
是对方的1.2倍
$500.4M
营收增速更快
FELE
高出5.2%
4.8%
净利率更高
RPRX
高出27.5%
6.9%
两年增速更快
RPRX
近两年复合增速
-4.0%
损益表 — Q1 FY2026 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $500.4M | $622.0M |
| 净利润 | $34.7M | $214.2M |
| 毛利率 | 35.0% | — |
| 营业利润率 | 9.6% | 62.4% |
| 净利率 | 6.9% | 34.4% |
| 营收同比 | 9.9% | 4.8% |
| 净利润同比 | 10.6% | 2.9% |
| 每股收益（稀释后） | $0.77 | $0.49 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收FELERPRX
| Q1 26 | $500.4M | — | ||
| Q4 25 | $506.9M | $622.0M | ||
| Q3 25 | $581.7M | $609.3M | ||
| Q2 25 | $587.4M | $578.7M | ||
| Q1 25 | $455.2M | $568.2M | ||
| Q4 24 | $485.7M | $593.6M | ||
| Q3 24 | $531.4M | $564.7M | ||
| Q2 24 | $543.3M | $537.3M |
净利润FELERPRX
| Q1 26 | $34.7M | — | ||
| Q4 25 | $39.3M | $214.2M | ||
| Q3 25 | $16.7M | $288.2M | ||
| Q2 25 | $60.1M | $30.2M | ||
| Q1 25 | $31.0M | $238.3M | ||
| Q4 24 | $33.7M | $208.2M | ||
| Q3 24 | $54.6M | $544.0M | ||
| Q2 24 | $59.1M | $102.0M |
毛利率FELERPRX
| Q1 26 | 35.0% | — | ||
| Q4 25 | 33.8% | — | ||
| Q3 25 | 35.9% | — | ||
| Q2 25 | 36.1% | — | ||
| Q1 25 | 36.0% | — | ||
| Q4 24 | 33.8% | — | ||
| Q3 24 | 35.7% | — | ||
| Q2 24 | 36.8% | — |
营业利润率FELERPRX
| Q1 26 | 9.6% | — | ||
| Q4 25 | 10.2% | 62.4% | ||
| Q3 25 | 14.6% | 70.1% | ||
| Q2 25 | 15.0% | 36.3% | ||
| Q1 25 | 9.7% | 94.0% | ||
| Q4 24 | 8.9% | 60.9% | ||
| Q3 24 | 13.8% | — | ||
| Q2 24 | 14.6% | 50.2% |
净利率FELERPRX
| Q1 26 | 6.9% | — | ||
| Q4 25 | 7.7% | 34.4% | ||
| Q3 25 | 2.9% | 47.3% | ||
| Q2 25 | 10.2% | 5.2% | ||
| Q1 25 | 6.8% | 41.9% | ||
| Q4 24 | 6.9% | 35.1% | ||
| Q3 24 | 10.3% | 96.3% | ||
| Q2 24 | 10.9% | 19.0% |
每股收益（稀释后）FELERPRX
| Q1 26 | $0.77 | — | ||
| Q4 25 | $0.87 | $0.49 | ||
| Q3 25 | $0.37 | $0.67 | ||
| Q2 25 | $1.31 | $0.07 | ||
| Q1 25 | $0.67 | $0.55 | ||
| Q4 24 | $0.73 | $0.46 | ||
| Q3 24 | $1.17 | $1.21 | ||
| Q2 24 | $1.26 | $0.23 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $80.4M | $618.7M |
| 总债务越低越好 | $134.4M | $9.0B |
| 股东权益账面价值 | $1.3B | $9.7B |
| 总资产 | $2.0B | $19.6B |
| 负债/权益比越低杠杆越低 | 0.10× | 0.92× |
8季度趋势，按日历期对齐
现金及短期投资FELERPRX
| Q1 26 | $80.4M | — | ||
| Q4 25 | $99.7M | $618.7M | ||
| Q3 25 | $102.9M | $938.9M | ||
| Q2 25 | $104.6M | $631.9M | ||
| Q1 25 | $84.0M | $1.1B | ||
| Q4 24 | $220.5M | $929.0M | ||
| Q3 24 | $106.3M | $950.1M | ||
| Q2 24 | $58.1M | $1.8B |
总债务FELERPRX
| Q1 26 | $134.4M | — | ||
| Q4 25 | $135.2M | $9.0B | ||
| Q3 25 | $135.2M | $8.9B | ||
| Q2 25 | $14.5M | $8.0B | ||
| Q1 25 | $14.9M | $7.6B | ||
| Q4 24 | $11.6M | $7.6B | ||
| Q3 24 | $11.6M | $7.6B | ||
| Q2 24 | $87.2M | $7.6B |
股东权益FELERPRX
| Q1 26 | $1.3B | — | ||
| Q4 25 | $1.3B | $9.7B | ||
| Q3 25 | $1.3B | $9.6B | ||
| Q2 25 | $1.3B | $9.5B | ||
| Q1 25 | $1.3B | $9.8B | ||
| Q4 24 | $1.3B | $10.3B | ||
| Q3 24 | $1.3B | $10.3B | ||
| Q2 24 | $1.2B | $9.8B |
总资产FELERPRX
| Q1 26 | $2.0B | — | ||
| Q4 25 | $1.9B | $19.6B | ||
| Q3 25 | $2.0B | $19.3B | ||
| Q2 25 | $2.0B | $18.3B | ||
| Q1 25 | $1.9B | $17.6B | ||
| Q4 24 | $1.8B | $18.2B | ||
| Q3 24 | $1.8B | $18.0B | ||
| Q2 24 | $1.8B | $17.7B |
负债/权益比FELERPRX
| Q1 26 | 0.10× | — | ||
| Q4 25 | 0.10× | 0.92× | ||
| Q3 25 | 0.10× | 0.93× | ||
| Q2 25 | 0.01× | 0.84× | ||
| Q1 25 | 0.01× | 0.78× | ||
| Q4 24 | 0.01× | 0.74× | ||
| Q3 24 | 0.01× | 0.74× | ||
| Q2 24 | 0.07× | 0.78× |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | — | $827.1M |
| 自由现金流经营现金流 - 资本支出 | — | — |
| 自由现金流率自由现金流/营收 | — | — |
| 资本支出强度资本支出/营收 | — | — |
| 现金转化率经营现金流/净利润 | — | 3.86× |
| 过去12个月自由现金流最近4个季度 | — | — |
8季度趋势，按日历期对齐
经营现金流FELERPRX
| Q1 26 | — | — | ||
| Q4 25 | $104.2M | $827.1M | ||
| Q3 25 | $102.7M | $702.6M | ||
| Q2 25 | $51.5M | $364.0M | ||
| Q1 25 | $-19.5M | $596.1M | ||
| Q4 24 | $110.3M | $742.5M | ||
| Q3 24 | $116.1M | $703.6M | ||
| Q2 24 | $36.4M | $658.2M |
自由现金流FELERPRX
| Q1 26 | — | — | ||
| Q4 25 | $88.7M | — | ||
| Q3 25 | $91.3M | — | ||
| Q2 25 | $39.9M | — | ||
| Q1 25 | $-26.3M | — | ||
| Q4 24 | $97.5M | — | ||
| Q3 24 | $106.6M | — | ||
| Q2 24 | $26.1M | — |
自由现金流率FELERPRX
| Q1 26 | — | — | ||
| Q4 25 | 17.5% | — | ||
| Q3 25 | 15.7% | — | ||
| Q2 25 | 6.8% | — | ||
| Q1 25 | -5.8% | — | ||
| Q4 24 | 20.1% | — | ||
| Q3 24 | 20.1% | — | ||
| Q2 24 | 4.8% | — |
资本支出强度FELERPRX
| Q1 26 | — | — | ||
| Q4 25 | 3.1% | — | ||
| Q3 25 | 2.0% | — | ||
| Q2 25 | 2.0% | — | ||
| Q1 25 | 1.5% | — | ||
| Q4 24 | 2.6% | — | ||
| Q3 24 | 1.8% | — | ||
| Q2 24 | 1.9% | — |
现金转化率FELERPRX
| Q1 26 | — | — | ||
| Q4 25 | 2.65× | 3.86× | ||
| Q3 25 | 6.14× | 2.44× | ||
| Q2 25 | 0.86× | 12.06× | ||
| Q1 25 | -0.63× | 2.50× | ||
| Q4 24 | 3.28× | 3.57× | ||
| Q3 24 | 2.13× | 1.29× | ||
| Q2 24 | 0.62× | 6.45× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
FELE
暂无分部数据
RPRX
| Financial Royalty Assets | $592.4M | 95% |
| Royalty Income Other | $29.6M | 5% |
